24/7 Market News Snapshot 05 February, 2025 – Accuray Incorporated (NASDAQ:ARAY)
DENVER, Colo., 05 February, 2025 (247marketnews.com) – (NASDAQ:ARAY) are discussed in this article.
Accuray Incorporated has displayed notable market strength, with its stock opening at $2.32 and recently trading at $2.431, reflecting a 4.33% increase. A trading volume of 1.59 million shares indicates strong investor interest, suggesting a positive market sentiment and potential for further growth. Technical analysis reveals that Accuray is likely breaking through key resistance levels, which could lead to additional gains. Traders are advised to keep an eye on support levels near the opening price and ongoing volume trends to confirm bullish momentum.
In conjunction with this market performance, Accuray has reported robust financial results for the second quarter of fiscal year 2025, which ended on December 31, 2024. The company achieved total net revenue of $116.2 million, an increase of 8% year-over-year. This growth is significantly attributed to a 19% rise in product revenue, totaling $61.2 million, showcasing sustained demand for Accuray’s innovative radiotherapy solutions.
Moreover, Accuray posted a net income of $2.5 million for the quarter, a remarkable turnaround from a net loss of $9.6 million in the same quarter last year. The company also improved its adjusted EBITDA to $9.6 million, highlighting enhanced operational efficiency, while successfully lowering operating expenses by 7%.
CEO Suzanne Winter emphasized the positive trends observed in emerging markets and increasing customer demand, particularly for the Tomo C System and the newly launched Helix system. The company has raised its fiscal year 2025 guidance, anticipating revenues between $463 million and $475 million and adjusted EBITDA of $28.5 million to $31.0 million. These projections indicate a steady recovery in the market and reflect Accuray’s commitment to improving patient care through innovative radiation therapy solutions.
Related news for (ARAY)
- Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
- Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
- Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results
- Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities
- Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025